About IDT Biologika

1. IDT Biologika 2016
IDT Biologika
Biologics for the 21st century

2. 2
IDT Biologika, Dessau Site
Integrated pharma- and biotechnology
IDT Biologika Corporate Presentation

3. 3
Vaccines and biologic parenterals
IDT Biologika – Two business models
IDT Biologika Corporate Presentation
Contract manufacturing
Development, industrialization and production of prophylactic and
therapeutic products using highly efficient manufacturing technologies
Long-term international technology and manufacturing partnerships
Animal Health
Innovative, groundbreaking solutions to fight infectious diseases in
animals
Own products are marketed worldwide

4. 4
The company in facts and figures
IDT Biologika Corporate Presentation
Owners
Hartmut, Carsten and Stefan Klocke via
the Klocke Group
Rating
Investment Grade
8%
of revenue
dedicated to
research &
development
+ €200
million
revenues in 2016
1,700
employees in 2016
€300 million
invested by IDT since
1993, €100 million
between 2011 and today
Worldwide
IDT works with
customers/partners
around the world

5. 5
Development of Revenues and Staff
IDT Biologika Corporate Presentation
Staff Revenues
€ millionA corporate strategy with a focus on globalization and
industrialization forms the basis for further growth

6. IDT Biologika
Thank you for your attention
2016